Is T2 Biosystems, Inc. (TTOO) a Buy, Sell, or Hold?
T2 Biosystems, Inc.
OTC:TTOO
$0.0007 USD
$0.0 (16.67%)
- Volume
- 35
- Average Volume
- 6.51K
- Market Capitalization
- $19.63K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $0.12
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.45
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Craig R. Jalbert |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | TTOO |
| CUSIP | 89853L302 |
| CIK | 0001492674 |
| Web | https://www.t2biosystems.com |
| Phone | 781 761 4646 |
| Currency | USD |
| Employees | 113 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.77 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.45 |
| Quick Ratio | 0.36 |
| Cash Ratio | 0.28 |
Sales & Book Value
| Annual Sales | $7.19M |
| Price / Sales | 0.00 |
| Cash Flow | -18.52 |
| Price / Cash Flow | 0.00 |
| Price / Book | 0.00 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -99.99% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-19.19 |
| Trailing P/E Ratio | 0.00 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-50.08M |
| Net Margin | -696.19% |
| Pretax Margin | -696.19% |
| Return on Equity | 147.27% |
| Return on Assets | -143.91% |
Financials Score
| AltmanZ Score | -55.57 |
| Piotroski Score | 3.00 |
| Working Capital | -14.65M |
| Total Assets | 18.08M |
| Ebit | -39.77M |
| Market Cap | 11.22K |
| Total Liabilities | 29.79M |
Poll Results
About T2 Biosystems, Inc. (OTC:TTOO) Stock
T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associ ... ated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus. In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloodstream infections caused by both bacterial and Candida species, along with antibiotic resistance markers; T2Cauris, which offers direct detection of the emerging superbug Candida auris in patient skin, blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel specifically engineered for the T2Dx Instrument to identify the bacteria responsible for Lyme disease. T2 Biosystems has also established strategic partnerships, such as its collaboration with Canon U.S. Life Sciences, Inc., to jointly develop a diagnostic test panel for Lyme disease. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Frequently Asked Questions
-
What is the current T2 Biosystems, Inc. (TTOO) stock price?
-
T2 Biosystems, Inc.(OTC:TTOO) stock price is $0.0007 in the last trading session. During the trading session, TTOO stock reached the peak price of $0.12 while $0.0001 was the lowest point it dropped to. The percentage change in TTOO stock occurred in the recent session was 16.67% while the dollar amount for the price change in TTOO stock was $0.0.
-
TTOO's industry and sector of operation?
-
The OTC listed TTOO is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of TTOO?
-
Brett A. Giffin | Chief Commercial Officer
Craig R. Jalbert CIRA | Chief Executive Officer, President, Corporate Treasurer, Corporate Secretary & Director
Kelley J. Morgan | Chief People Officer
Roger Smith | Senior Vice President of Science Research & Development
| -
How many employees does TTOO have?
-
Number of TTOO employees currently stands at 113. TTOO operates from 101 Hartwell Avenue, Lexington, MA 02421, US.
-
Link for TTOO official website?
-
Official Website of TTOO is: https://www.t2biosystems.com
-
How do I contact TTOO?
-
TTOO could be contacted at phone #781 761 4646 and can also be accessed through its website. TTOO operates from 101 Hartwell Avenue, Lexington, MA 02421, US.
-
How many shares of TTOO are traded daily?
-
The average number of TTOO shares traded daily for last 3 months was 6.51K.
-
What is the market cap of TTOO currently?
-
The market value of TTOO currently stands at $19.63K with its latest stock price at $0.0007